trending Market Intelligence /marketintelligence/en/news-insights/trending/kZg5NBsZ17XyJCyjlPnW_w2 content esgSubNav
In This List

Roche to collaborate with Idorsia in oncology research

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Roche to collaborate with Idorsia in oncology research

Roche Holding AG secured an option to exclusively develop and market Idorsia Ltd.'s oncology compounds as part of a research collaboration.

Roche will pay Idorsia an upfront payment of CHF15 million for the collaboration and can exclusively license compounds resulting from the collaboration and certain Idorsia compounds for a further payment of CHF35 million, after a pre-determined period.

Idorsia will also be eligible for one-time development and regulatory milestones of up to CHF410 million, sales-threshold based milestones and tiered royalties on annual net sales of all products resulting from the collaboration.

The companies will form a joint committee for the collaborative research, chaired by Idorsia.